Compare Stocks: TNXP, BBOT, IRWD, and ALLO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$2.01 +2.0%	$1.95	$0.99 ▼ $4.46	$693.76M	0.48	6.39 million shs	3.69 million shs
BBOT BridgeBio Oncology Therapeutics	$9.33 +6.3%	$8.19	$7.00 ▼ $14.87	$747.40M	0.36	312,491 shs	219,409 shs
IRWD Ironwood Pharmaceuticals	$4.32 +1.4%	$3.90	$0.81 ▼ $5.78	$704.41M	0.2	2.18 million shs	1.84 million shs
TNXP Tonix Pharmaceuticals	$12.03 +3.3%	$11.61	$9.40 ▼ $69.97	$191.77M	1.69	489,049 shs	386,772 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+6.91%	-4.29%	-11.84%	+89.62%
BBOT BridgeBio Oncology Therapeutics	0.00%	+15.33%	+2.64%	+21.80%	+932,999,900.00%
IRWD Ironwood Pharmaceuticals	0.00%	+2.13%	-7.49%	+2.37%	+436.65%
TNXP Tonix Pharmaceuticals	0.00%	+20.18%	-7.67%	-14.62%	-73.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$2.01 +2.0%	$1.95	$0.99 ▼ $4.46	$693.76M	0.48	6.39 million shs	3.69 million shs
BBOT BridgeBio Oncology Therapeutics	$9.33 +6.3%	$8.19	$7.00 ▼ $14.87	$747.40M	0.36	312,491 shs	219,409 shs
IRWD Ironwood Pharmaceuticals	$4.32 +1.4%	$3.90	$0.81 ▼ $5.78	$704.41M	0.2	2.18 million shs	1.84 million shs
TNXP Tonix Pharmaceuticals	$12.03 +3.3%	$11.61	$9.40 ▼ $69.97	$191.77M	1.69	489,049 shs	386,772 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+6.91%	-4.29%	-11.84%	+89.62%
BBOT BridgeBio Oncology Therapeutics	0.00%	+15.33%	+2.64%	+21.80%	+932,999,900.00%
IRWD Ironwood Pharmaceuticals	0.00%	+2.13%	-7.49%	+2.37%	+436.65%
TNXP Tonix Pharmaceuticals	0.00%	+20.18%	-7.67%	-14.62%	-73.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.52	323.99% Upside
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.80	165.81% Upside
IRWD Ironwood Pharmaceuticals	2.43	Hold	$6.23	44.29% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.00	99.50% Upside

Current Analyst Ratings Breakdown

Latest TNXP, BBOT, IRWD, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	IRWD Ironwood Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/24/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/13/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	BBOT BridgeBio Oncology Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight
7/8/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$27.00
7/1/2026	IRWD Ironwood Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/24/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$26.00
6/24/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/22/2026	BBOT BridgeBio Oncology Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$22.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
IRWD Ironwood Pharmaceuticals	$296.15M	2.38	$0.26 per share	16.78	($0.99) per share	-4.36
TNXP Tonix Pharmaceuticals	$13.11M	14.63	N/A	N/A	$19.17 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.77	N/A	N/A	N/A	N/A	-56.45%	-40.36%	8/12/2026 (Estimated)
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.05	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.61	N/A	N/A	33.36%	-58.38%	34.93%	N/A
TNXP Tonix Pharmaceuticals	-$124.02M	-$14.36	N/A	N/A	N/A	-839.52%	-67.65%	-60.47%	8/10/2026 (Estimated)

Latest TNXP, BBOT, IRWD, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	N/A	N/A	N/A	$0.00 million	N/A
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.6425	N/A	N/A	N/A	$7.72 million	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
5/13/2026	Q1 2026	ALLO Allogene Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	$0.00 million	N/A
5/12/2026	Q1 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$526.11	N/A	-$526.11	N/A	N/A
5/11/2026	Q1 2026	TNXP Tonix Pharmaceuticals	-$2.54	-$2.93	-$0.39	-$2.93	$6.13 million	$6.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.65	9.65
BBOT BridgeBio Oncology Therapeutics	N/A	6.16	6.16
IRWD Ironwood Pharmaceuticals	N/A	6.06	1.41
TNXP Tonix Pharmaceuticals	N/A	6.99	6.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
BBOT BridgeBio Oncology Therapeutics	54.89%
IRWD Ironwood Pharmaceuticals	N/A
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
BBOT BridgeBio Oncology Therapeutics	24.40%
IRWD Ironwood Pharmaceuticals	9.30%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	345.16 million	299.60 million	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.11 million	60.56 million	N/A
IRWD Ironwood Pharmaceuticals	220	163.06 million	147.89 million	Optionable
TNXP Tonix Pharmaceuticals	50	15.94 million	15.62 million	Not Optionable

TNXP, BBOT, IRWD, and ALLO Headlines

Recent News About These Companies

Tonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on Monday

August 9 at 2:26 AM | americanbankingnews.com

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

August 5, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

August 5, 2026 | globenewswire.com

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent ...

August 3, 2026 | markets.businessinsider.com

Tonix Pharmaceuticals (TNXP) Expected to Release Earnings on Monday

August 3, 2026 | marketbeat.com

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

August 3, 2026 | finance.yahoo.com

Tonix Pharma Advances Phase 2 Lyme Disease Vaccine Study

August 3, 2026 | tipranks.com

August 3, 2026 | globenewswire.com

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

July 27, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Holding Corp. to Host Second Quarter 2026 Financial Results Conference Call and Webcast

July 27, 2026 | quiverquant.comQ

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

July 27, 2026 | globenewswire.com

Tonix Pharma announces upcoming retirement of chief medical officer

July 21, 2026 | tipranks.com

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

July 15, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

July 15, 2026 | globenewswire.com

Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)

July 13, 2026 | investorshub.advfn.com

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

July 13, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered Lives

July 13, 2026 | quiverquant.comQ

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

July 13, 2026 | globenewswire.com

Tonix Pharmaceuticals Holding Corp (TNXP) Stock Price, Quote, News & History

July 10, 2026 | benzinga.com

Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, News, Quote & History - Yahoo Finance

July 2, 2026 | finance.yahoo.com

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

June 29, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TNXP, BBOT, IRWD, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$2.01 +0.04 (+2.03%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/7/2026 07:38 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$9.33 +0.55 (+6.26%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$9.32 -0.01 (-0.11%)

As of 08/7/2026 07:34 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.32 +0.06 (+1.41%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.26 -0.06 (-1.37%)

As of 08/7/2026 07:52 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Tonix Pharmaceuticals NASDAQ:TNXP

$12.03 +0.38 (+3.26%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$11.90 -0.13 (-1.06%)

As of 08/7/2026 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, BBOT, IRWD, and ALLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, BBOT, IRWD, and ALLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, BBOT, IRWD, and ALLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TNXP, BBOT, IRWD, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Ironwood Pharmaceuticals NASDAQ:IRWD

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, BBOT, IRWD, and ALLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, BBOT, IRWD, and ALLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, BBOT, IRWD, and ALLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TNXP, BBOT, IRWD, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Ironwood Pharmaceuticals NASDAQ:IRWD

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools